

Electronically filed on February 13, 2007

<b>PETITION FOR CERTIFICATE OF CORRECTION</b>  <b>USPTO ERROR</b>  Address to: Mail Stop DAC Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	AREN-023CIP3
	First Named Inventor	LIAW, CHEN W.
	Patent Number	7,119,190
	Issue Date	October 10, 2006
	Application Number	10/083,168
	Filing Date	February 26, 2002
	Title:	<i>"ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G PROTEIN- COUPLED RECEPTORS"</i>

Sir:

This is to request correction of U.S. Patent No. 7,119,190 under 37 C.F.R. 1.322. A form PTO/SB/44 is provided herewith, showing the requested correction:

On December 25, 2005, in response to an Official Action dated July 25, 2005, claims 37-50 were amended in the U.S. Patent Application 10/083,168 now US Patent No. 7,119,190. However, some of the amendments do not appear in the issued claims 1, 2 and 3, former claims 37-39, respectively, as follows:

Claim 1: "SEQ. ID.: 16" should read as "SEQ. ID. NO.: 16".

Claim 2: please correct to read "An isolated polynucleotide encoding a non-endogenous constitutively activated version of a wild-type G protein-couple receptor, wherein the wild-type G protein-coupled receptor comprises SEQ. ID. NO.:16 and wherein said polynucleotide encodes an amino acid sequence that comprises SEQ. ID. NO.:85."

Claim 3: please correct to read: "An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises SEQ. ID. No.: 84."


As such, Patentees respectfully request a Certificate of Correction, correcting claims 1, 2, and 3 as shown in the attached PTO/SB/44 form.

Copies of relevant page 3 of the above amendment and pages 163 and 164 of Patent No. US 7,119,190 B2, as issued, are submitted herewith.

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number AREN-023CIP3.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

By:   
Carol L. Francis, Ph.D.  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : US 7,119,190 B2  
DATED : Oct 10, 2006  
INVENTOR(S) : LIAW, CHEN W., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1: "SEQ. ID.: 16" should read as "SEQ. ID. NO.: 16".

Claim 2: please correct to read "An isolated polynucleotide encoding a non-endogenous constitutively activated version of a wild-type G protein-couple receptor, wherein the wild-type G protein-coupled receptor comprises SEQ. ID. NO.:16 and wherein said polynucleotide encodes an amino acid sequence that comprises SEQ. ID. NO. 85."

Claim 3: please correct to read: "An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises SEQ. ID. No.: 84."

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303

PATENT NO.

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-36. (Canceled)

37. (Currently amended) An isolated polynucleotide encoding a non-endogenous, constitutively activated version of a wild-type G protein-coupled receptor, wherein the wild-type G protein-coupled receptor comprises ~~SEQ. ID. NO.: 2, SEQ. ID. NO.: 4, SEQ. ID. NO.: 6, SEQ. ID. NO.: 8, SEQ. ID. NO.: 10, SEQ. ID. NO.: 12, SEQ. ID. NO.: 14, SEQ. ID. NO.: 16, SEQ. ID. NO.: 18, or SEQ. ID. NO.: 98~~ and wherein said non-endogenous constitutively activated version contains a mutation of an amino acid residue located 16 amino acid residues from a proline residue in TM6.

38. (Currently amended) An isolated polynucleotide ~~according to claim 37~~ encoding a non-endogenous, constitutively activated version of a wild-type G protein-coupled receptor, wherein the wild-type G protein-coupled receptor comprises SEQ. ID. NO.: 16, and wherein said polynucleotide encodes an amino acid sequence that comprises ~~SEQ. ID. NO.: 63, SEQ. ID. NO.: 65, SEQ. ID. NO.: 67, SEQ. ID. NO.: 69, — SEQ. ID. NO.: 71, SEQ. ID. NO.: 73, SEQ. ID. NO.: 75, SEQ. ID. NO.: 77, SEQ. ID. NO.: 79, SEQ. ID. NO.: 81, SEQ. ID. NO.: 83, SEQ. ID. NO.: 85, or SEQ. ID. NO.: 87.~~

39. (Currently amended) An isolated polynucleotide according to claim 38, wherein the polynucleotide comprises ~~SEQ. ID. NO.: 62, SEQ. ID. NO.: 64, SEQ. ID. NO.: 66, SEQ. ID. NO.: 68, SEQ. ID. NO.: 70, SEQ. ID. NO.: 72, SEQ. ID. NO.: 74, SEQ. ID. NO.: 76, SEQ. ID. NO.: 78, SEQ. ID. NO.: 80, SEQ. ID. NO.: 82, SEQ. ID. NO.: 84, or SEQ. ID. NO.: 86.~~

40. (Previously presented) A vector comprising a polynucleotide according to any one of claims 37 to 39.

-continued

<213> ORGANISM: Unknown  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Novel Sequence

<400> SEQUENCE: 99

cgagaagggtg ctcaagggtg c

21

<210> SEQ ID NO 100  
 <211> LENGTH: 30  
 <212> TYPE: DNA  
 <213> ORGANISM: Unknown  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Novel Sequence

<400> SEQUENCE: 100

gagaagagct ccactagcct ggtgatcaca

30

<210> SEQ ID NO 101  
 <211> LENGTH: 36  
 <212> TYPE: DNA  
 <213> ORGANISM: Unknown  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Novel Sequence

<400> SEQUENCE: 101

gaattcatga actcgtggga cgcgggcctg gcgggc

36

<210> SEQ ID NO 102  
 <211> LENGTH: 32  
 <212> TYPE: DNA  
 <213> ORGANISM: Unknown  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Novel Sequence

<400> SEQUENCE: 102

ctcgagtcac tcagacacg gcagaatgtt ct

32

What is claimed is:

1. An isolated polynucleotide encoding a non-endogenous, constitutively activated version of a wild-type G protein-coupled receptor, wherein the wild-type G protein-coupled receptor comprises SEQ. ID.: 16 and wherein said non-endogenous constitutively activated version contains a mutation of an amino acid residue located 16 amino acid residues from a proline residue in TM6.

2. An isolated polynucleotide encoding a non-endogenous, constitutively activated version of a wild-type G protein-coupled receptor, wherein the wild-type G protein-coupled receptor comprises SEQ. ID. NO.: 16, and wherein said polynucleotide encodes an amino acid sequence that comprises.

3. An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises.

4. A vector comprising a polynucleotide according to any one of claims 1 to 3.

40 5. A vector according to claim 4, wherein said vector is an expression vector.

6. A host cell comprising an expression vector according to claim 5.

45 7. A process for making a recombinant host cell comprising the steps of:

(a) transfecting an expression vector according to claim 5 into a suitable host cell; and

50 (b) culturing the host cell under conditions which allow expression of a G protein-coupled receptor from the expression vector.

8. A membrane of a recombinant host cell produced by the process of claim 7 comprising said G protein-coupled receptor.

\* \* \* \* \*

COPY